
Are you taking Ozempic, Wegovy, or other GLP-1 drug for weight loss? Here's what to know about the costs.
Whether GLP-1s are covered by insurance has huge implications nationally because the drugs, which were first approved to treat diabetes and later obesity, are also being studied for possible future treatment of a
Advertisement
Here's what you should know about GLP-1s and how they're covered.
How much do GLP-1 drugs cost out of pocket?
The monthly price ranges from about $950 to $1,350, which adds up to more than $11,000 a year, at a minimum, before insurance and discounts.
Advertisement
What are the brand names of GLP-1s?
Ozempic and Wegovy are two of the most well-known, due to extensive TV and marketing efforts. Others are Mounjaro, Saxenda, Trulicity, and Zepbound. GLP-1s are currently considered the world's hottest pharmaceutical products.
What does GLP-1 stand for?
Glucagon-like peptide. It is a hormone that plays a crucial role in regulating blood sugar, appetite, and digestion. It works primarily by stimulating insulin release, suppressing glucagon secretion, slowing gastric emptying, and increasing a feeling of fullness after eating.
Will other insurers follow Blue Cross's example by eliminating GLP-1 coverage?
Blue Cross is the dominant and most influential commercial health insurer in the state, with 3 million members. It's hard to imagine that Point32Health, the next largest commercial insurer with 1.5 million members, will continue to compete with Blue Cross at a significant financial disadvantage by covering expensive GLP-1s.
Will my employer help defray the cost if my GLP-1 coverage is ended?
There is a chance your employer will pick up at least some of the cost because doing so may help in employee recruitment and retention. But there is less flexibility for employers to do so if they have fewer than 100 employees and are 'fully insured,' as opposed to 'self-insured.' (Blue Cross and Point32Health offer both types of plans — more on this below.)
How does a fully insured plan work?
Smaller employers often avoid some of the risk of health insurance losses by contracting with an insurer such as Blue Cross to assume the risk of huge, unforeseen spikes in claims. (Those insurers also administer the plan.) When an insurer assumes the risk, it controls all aspects of the plan, including what drugs are — and are not — covered. In these circumstances, an employer has little discretion to add coverage of a drug such as GLP-1s. They must strictly adhere to the plan as designed by their insurer.
How does the size of the company affect insurance?
Because of the popularity of GLP-1s, Blue Cross is allowing more flexibility than usual for fully insured companies. Ordinarily, it would allow no variances in its plans. But for GLP-1s, it is allowing employers to continue to offer coverage of GLP-1s, so long as the companies agree to pay significant increases in premiums. But the option to continue coverage of GLP-1s is not available to companies of 100 or fewer employees because it is deemed too risky to the insurer.
Advertisement
How does a self-insured plan work?
Self-insured employers are bigger companies with more resources that hire an insurer like Blue Cross to administer an insurance plan, but the employer assumes the risk of claims exceeding premiums. Because they pay their own claims, they are free to make changes in the plans they offer, including by adding coverage of GLP-1s (with an increase in premiums paid by employees).
How should I approach my employer about what drugs are covered in my insurance plan?
Insurance coverage is among the most important benefits offered by employers. (More than half of the state's residents are covered by an employer-sponsored health plan.) If you belong to a union, health insurance is a major component of contract negotiations. If you are choosing between job offers, the quality of the offered insurance may be a big factor in your decision. If GLP-1 coverage is important to you, make sure your views are communicated to your employer's decision makers.
Why would an employer opt to cover GLP-1s?
Besides recruitment and retention, a company may see GLP-1s as a path to lower its costs in the long run because weight loss generally improves health and could result in fewer and less expensive claims later. Some see GLP-1s as possibly significantly lowering overall future health costs.
How do I know if my employer is fully insured or self-insured?
Contact your company's HR department or check your health insurance paperwork. On the back of my insurance ID card it says my insurer 'administers claims payments and does not assume financial risk,' meaning my plan is self-insured.
Advertisement
Are GLP-1s covered by Medicare?
Medicare does not cover GLP-1s prescribed solely for weight loss. But it does cover GLP-1s prescribed to reduce the risk of heart attack and stroke due to cardiovascular disease and obesity or being overweight.
President Trump upon taking office reversed the Biden administration's plan to expand Medicare coverage by including GLP-1s for weight loss.
Do Medicare supplemental plans cover GLP-1s?
They usually follow Medicare policies, so, generally, no, GLP-1s are not covered for weight loss.
Are GLP-1s covered by MassHealth?
MassHealth covers Zepbound for treatment for weight loss.
What's the future of the industry?
Drug companies are racing to produce GLP-1s in the form of a daily pill instead of requiring weekly injections, among other potential advances. They are also trying to reduce the side effects of these drugs.
Will the cost of GLP-1s eventually decline?
Yes, prices are expected to drop due to increased competition, generic versions, potential price negotiation in Medicare, and other factors. But increased demand could
Are 'compounded' versions of GLP-1s available?
Compounded drugs are made by pharmacies and are typically allowed by the Food and Drug Administration to augment supply when there's a shortage of the brand-name drug (though they are not FDA-approved). Such a shortage existed for some GPL-1s, but the FDA this month said the shortage has been resolved. The compounded drugs are
Got a problem? Send your consumer issue to

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
an hour ago
- Business Insider
AstraZeneca announces $50B of investment in U.S. by 2030
AstraZeneca (AZN) announces $50B of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar U.S. manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5B announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. 'The $50B investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland; State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts; Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; Continuous manufacturing expansion in Mount Vernon, Indiana; Specialty manufacturing expansion in Coppell, Texas; New sites to supply clinical trials. Our growing research and development investment in novel medicines. Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80B in Total Revenue by 2030, of which we expect 50% would be generated in the U.S.' Elevate Your Investing Strategy:


Business Wire
7 hours ago
- Business Wire
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. The $50 billion investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California Continuous manufacturing expansion in Mount Vernon, Indiana Specialty manufacturing expansion in Coppell, Texas New sites to supply clinical trials Our growing research and development investment in novel medicines Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.' Governor Glenn Youngkin, Commonwealth of Virginia, said: 'I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.' Pascal Soriot, Chief Executive Officer, AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines.' Notes AstraZeneca in the US The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. We employ more than 18,000 people and support 92,000 jobs overall across the United States. In 2024 we contributed $5 billion directly to the economy and created approximately $20 billion worth of overall value for the American economy. Today the US represents 42% of our Total Revenue with an ambition to reach 50% by 2030. This underscores the critical role the US plays in our ability to deliver on our ambition to launch 20 new medicines by the end of the decade. AstraZeneca AstraZeneca (Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit and follow the Company on social media @AstraZeneca.
Yahoo
7 hours ago
- Yahoo
AstraZeneca announces $50 billion U.S. manufacturing investment, matching its big pharma peers
AstraZeneca (AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers that have, combined, announced more than $200 billion in investments in coming years. The commitment is the largest investment to-date, according to the company in a statement Monday. It includes expansions of current sites, including in Maryland and Massachusetts, as well as new facility in Virginia. "The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of the-art centre will produce small molecules, peptides and oligonucleotides," the company said. U.K.-based AstraZeneca said it currently relies on the U.S. market for 42% of its revenues, and hopes to increase the U.S. market share to 50% with this move. Its known for oncology drugs Tagrisso and Imfinzi. AstraZeneca's leadership was scheduled to speak at an event in Washington, D.C. Monday evening, flanked by Virginia Gov. Glenn Youngkin and U.S. Commerce Dept. representatives. "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030," said CEO Pascal Soriot. The strategy to invest billions in manufacturing is one being deployed by the industry in order to curry favor with President Donald Trump and his re-shoring agenda, and in hopes of avoiding strict tariffs on imported drug components manufactured abroad. Some of the largest investment commitments to-date have been Johnson & Johnson's (JNJ) $55 billion announcement and Eli Lilly's (LLY) $50 billion. With a previous $3.5 billion announced in November 2024, the new $50 billion commitment puts AstraZeneca in second. Trump has promised the pharma industry will face tariffs starting August 1. Industry leaders have pleaded with the administration for more time, and Trump has hinted the tariffs could be phased-in, as the companies work to bring their manufacturing onshore. The industry has been hoping Trump would ease up on the tariffs, in exchange for the onshoring commitments. J&J CFO Joe Wolk recently told Yahoo Finance the company has met with Trump and tried to persuade him to understand that the industry can't move facilities overnight. Meanwhile, others, like Eli Lilly CEO Dave Ricks, are hoping the administration would halt tariffs on the industry altogether. Ricks previously said that if the administration wants a commitment to make generics and other low-revenue products in exchange for no tariffs, its something the industry could consider. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data